Recent antiviral strategies against human coronavirus-related respiratory illnesses

被引:8
作者
Golda, Anna [1 ]
Pyrc, Krzysztof [1 ]
机构
[1] Jagiellonian Univ, Dept Microbiol, Fac Biochem Biophys & Biotechnol, PL-30387 Krakow, Poland
关键词
antiviral drugs; antiviral strategies; coronaviruses;
D O I
10.1097/MCP.0b013e3282f7646f
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review The main purpose of this review is to summarize the current research (2006-2007) concerning the development of novel anticoronaviral strategies and compounds. Recent findings Recent research led to the identification of several novel agents inhibiting coronaviral replication. The most promising compounds include carbohydrate-binding agents, neutralizing antibodies and drugs targeting a coronaviral envelope protein. Summary Although initial outbreaks of coronavirus that causes severe acute respiratory syndrome (SARS-CoV) were controlled by public health measures, the development of vaccines and antiviral agents for SARS-CoV is essential for improving control and treatment of future outbreaks. Four years after the SARS-CoV epidemic, several compounds with an anticoronaviral activity have been identified.
引用
收藏
页码:248 / 253
页数:6
相关论文
共 77 条
[1]   An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors [J].
Al-Gharabli, Samer I. ;
Shah, Syed T. Ali ;
Weik, Steffen ;
Schmidt, Marco F. ;
Mesters, Jeroen R. ;
Kuhn, Daniel ;
Klebe, Gerhard ;
Hilgenfeld, Rolf ;
Rademann, Joerg .
CHEMBIOCHEM, 2006, 7 (07) :1048-1055
[2]   Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[3]   Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy [J].
Balzarini, Jan .
NATURE REVIEWS MICROBIOLOGY, 2007, 5 (08) :583-597
[4]   Inhibition of respiratory viruses by nasally administered siRNA [J].
Bitko, V ;
Musiyenko, A ;
Shulyayeva, O ;
Barik, S .
NATURE MEDICINE, 2005, 11 (01) :50-55
[5]   Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides [J].
Bosch, BJ ;
Martina, BEE ;
van der Zee, R ;
Lepault, J ;
Haijema, BJ ;
Versluis, C ;
Heck, AJR ;
de Groot, R ;
Osterhaus, ADME ;
Rottier, PJM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (22) :8455-8460
[6]   CORONAVIRUS IBV - STRUCTURAL CHARACTERIZATION OF THE SPIKE PROTEIN [J].
CAVANAGH, D .
JOURNAL OF GENERAL VIROLOGY, 1983, 64 (DEC) :2577-2583
[7]   Can siRNAs conquer SARS? [J].
Chang, Z. ;
Hu, J. .
GENE THERAPY, 2006, 13 (11) :871-872
[8]   Binding interaction of quereetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro:: Structure-activity relationship studies reveal salient pharmacophore features [J].
Chen, Lili ;
Li, Jian ;
Luo, Cheng ;
Liu, Hong ;
Xu, Weijun ;
Chen, Gang ;
Liew, Oi Wah ;
Zhu, Weiliang ;
Puah, Chum Mok ;
Shen, Xu ;
Jiang, Hualiang .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (24) :8295-8306
[9]   Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse® [J].
Coughlin, Melissa ;
Lou, Gin ;
Martinez, Osvaldo ;
Masterman, Stephanie K. ;
Olsen, Ole A. ;
Moksa, Angelica A. ;
Farzan, Michael ;
Babcook, John S. ;
Prabhakar, Bellur S. .
VIROLOGY, 2007, 361 (01) :93-102
[10]   In vitro inhibition of SARS virus replication by human Interferons [J].
Dahl, H ;
Linde, A ;
Strannegård, Ö .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (11-12) :829-831